Filters: keyword is Midazolam [Clear All Filters]
- 2006
Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery,
Anesthesiology, vol. 105, no. 6, pp. 1135-46. DOI
- 2003
Mechanism-based modeling of the pharmacodynamic interaction of alphaxalone and midazolam in rats,
J Pharmacol Exp Ther, vol. 307, no. 2, pp. 765-75. DOI
- 2002
Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol,
J Pharmacokinet Pharmacodyn, vol. 29, no. 3, pp. 235-50.
Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers,
Br J Clin Pharmacol, vol. 53, no. 2, pp. 133-9. DOI
- 1999
Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam,
J Pharmacol Exp Ther, vol. 289, no. 2, pp. 1067-74.
Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats,
Br J Pharmacol, vol. 127, no. 1, pp. 227-35. DOI
- 1998
Adaptive changes in the pharmacodynamics of midazolam in different experimental models of epilepsy: kindling, cortical stimulation and genetic absence epilepsy,
Br J Pharmacol, vol. 125, no. 4, pp. 615-20. DOI
Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam,
J Pharmacol Exp Ther, vol. 284, no. 1, pp. 202-7.
- 1995
Pharmacodynamic interaction between midazolam and a low dose of ethanol in vivo,
Life Sci, vol. 57, no. 4, pp. 325-33. DOI
- 1993
A comparison of the concentration-effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity,
Br J Clin Pharmacol, vol. 36, no. 2, pp. 109-15.
- 1992
Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats,
Br J Pharmacol, vol. 107, no. 1, pp. 171-7.
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers,
Clin Pharmacol Ther, vol. 51, no. 6, pp. 715-28.
In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil,
J Pharmacol Exp Ther, vol. 260, no. 1, pp. 36-44.
In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy,
J Pharmacol Exp Ther, vol. 261, no. 1, pp. 56-61.
- 1991
A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat,
J Pharmacokinet Biopharm, vol. 19, no. 5, pp. 485-96.
Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration,
Br J Pharmacol, vol. 102, no. 3, pp. 663-8.
Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis,
Clin Pharmacokinet, vol. 20, no. 6, pp. 497-508.
The influence of dosage time of midazolam on its pharmacokinetics and effects in humans,
Clin Pharmacol Ther, vol. 50, no. 1, pp. 16-24.
- 1990
Quantification of the EEG effect of midazolam by aperiodic analysis in volunteers. Pharmacokinetic/pharmacodynamic modelling,
Clin Pharmacokinet, vol. 18, no. 3, pp. 245-53.
- 1988
Pharmacokinetic-pharmacodynamic modeling of midazolam effects on the human central nervous system,
Clin Pharmacol Ther, vol. 44, no. 1, pp. 14-22. DOI


